Post by
Kruisip on Jan 13, 2021 6:01am
Virtual roadshow: sales to grow from C$11.5 to C$40 million
On December 15th Medicure posted a new presentation on its website. It was the first time that the company got very explicit about expected sales for the coming years. The sales momentum is now underway, driven by Zypitamag. The product has a potential of C$30 million (as a comparison: sales of Medicure in 2020 were circa C$14 million. As the gross margin of Zypitamag is above 80% the contribution to net earnings will be significant. Later on other products are expected to add to the sales momentum.
Presentation.
Sales first nine months of 2020: C$11.5 million; Expected sales 2021 C$18 million, 2022: C$27 million, 2023 C$37 million.
Not included in the presentation is the sales potential of its legacy product MC-1; on January 7th Medicure posted news on the subject.
The current market cap. of C$15 million, low by any standards, reflects declining sales and profit figures during the last few years. If expectations as formulated in the presentation are realized, the shares will move higher.
Comment by
prophetoffacts on Jan 13, 2021 10:37am
This post has been removed in accordance with Community Policy